Multiple Radioiodine-avid Skin Metastases From Thyroid Carcinoma Detected on Posttherapy 131 I SPECT/CT.

Clin Nucl MedAug 12, 2026 (epub)
Case ReportNuclear MedicineDermatologyOncology (Medical)Radiology (Diagnostic)

Enes Yerdes, Merve Okuyan, Umut Elboga

✦ AI-curated · Sources linked

Case in brief

A 77-year-old man with papillary thyroid carcinoma had achieved remission after radioactive iodine treatment for metastatic disease. Eight years later, rising serum thyroglobulin prompted evaluation, and biopsy of newly detected skin lesions confirmed metastases. Posttherapy 131 I SPECT/CT following 200 mCi showed multiple radioiodine-avid cutaneous lesions on the scalp, left auricular region, anterior chest wall, and back.

What made this case unusual

The case combined multifocal cutaneous metastases at several sites with radioiodine avidity, detected after a long disease-free interval.

Diagnostic / clinical pearl

In a patient with prior metastatic papillary thyroid carcinoma and rising thyroglobulin, new skin lesions may represent metastases; biopsy and posttherapy 131 I SPECT/CT can establish their nature and distribution.

Source

PubMed · PMID 42606007

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nuclear Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.